| TRADING CENTER |
| Systemic Treatment With AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protei... - Market Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 57.22 | 0.49 / 0.86% | 10.94 |
| GILD | Gilead Sciences Inc | 43.24 | 0.08 / 0.19% | 16.69 |
| CELG | Celgene Corporation | 56.29 | 0.20 / 0.36% | 67.82 |
| 2008 Revenue: | $21.3 M | Headquarters: Corvallis, OR |
| Employees: | 83 | CEO: Dr. Leslie Hudson, Ph.D. |
| Net Income: | $-23,952,625.0 | Industry: Biotechnology |
| Market Cap: | $164.5 M | Website: www.antivirals.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| AVII | 1.61 | +0.12 / +8.05% | 1.49 | 1.62 | 1.52 | Profile Chart News |